Achilles Therapeutics plc - American Depositary Shares (NQ:ACHL)

1.480 UNCHANGED

Last Price Updated: 4:00 PM EDT, Mar 20, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Achilles Therapeutics plc - American Depositary Shares

< Previous 1 2 3 Next >

Achilles Therapeutics: Q1 Earnings Insights ↗

May 10, 2023

Via Benzinga

Achilles Therapeutics Reports First Quarter 2023 Financial Results and Recent Business Highlights

May 10, 2023

From Achilles Therapeutics PLC

Via GlobeNewswire

Achilles Therapeutics’ New Immunogenicity Prediction Application of its AI-Powered PELEUS™ Platform Uniquely Identifies the Most Potent T Cell Antigens

May 10, 2023

- New AI module delivers a "Target-to-T cell” approach for revolutionizing the identification and prioritization of targets for personalized antigen approaches -

From Achilles Therapeutics PLC

Via GlobeNewswire

Achilles Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement

April 25, 2023

Achilles ADSs will continue to trade on the Nasdaq Global Select Market at this time, and the Company’s operations are not affected by the receipt of the Notice

From Achilles Therapeutics PLC

Via GlobeNewswire

Recap: Achilles Therapeutics Q2 Earnings ↗

August 09, 2022

Achilles Therapeutics (NASDAQ:ACHL) reported its Q2 earnings results on Tuesday, August 9, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

Via Benzinga

Achilles Therapeutics Announces Grant of US Patent Covering the Treatment of Patients with an Immunotherapy Targeting Neoantigens Based on Tumor HLA Status

April 25, 2023

From Achilles Therapeutics PLC

Via GlobeNewswire

Achilles Therapeutics to Present at Chardan’s 7th Annual Genetic Medicines and Cell Therapy Manufacturing Summit

April 17, 2023

From Achilles Therapeutics PLC

Via GlobeNewswire

Achilles Therapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Recent Business Highlights

March 07, 2023

From Achilles Therapeutics PLC

Via GlobeNewswire

Achilles Therapeutics: Q1 Earnings Insights ↗

May 10, 2022

Achilles Therapeutics (NASDAQ:ACHL) reported its Q1 earnings results on Tuesday, May 10, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

Via Benzinga

Stocks That Hit 52-Week Lows On Friday ↗

February 04, 2022

On Friday, 209 companies set new 52-week lows. Interesting Facts About Today's 52-Week Lows: Meta Platforms (NASDAQ:FB) was the largest firm on a market cap...

Via Benzinga

12 Health Care Stocks Moving In Friday's After-Market Session ↗

January 13, 2023

Via Benzinga

12 Health Care Stocks Moving In Friday's After-Market Session ↗

January 06, 2023

Via Benzinga

Achilles Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

December 20, 2022

From Achilles Therapeutics PLC

Via GlobeNewswire

Achilles Therapeutics Presents Encouraging Phase I/IIa Update on Clonal Neoantigen Reactive T Cells in Advanced NSCLC and Melanoma at ESMO IO Congress 2022

December 06, 2022

From Achilles Therapeutics PLC

Via GlobeNewswire

Why UiPath Shares Are Trading Higher By Around 8%; Here Are 24 Stocks Moving Premarket ↗

December 02, 2022

Gainers

Via Benzinga

Achilles Therapeutics to Present Early Proof of Concept of Safety and Clinical Activity of Clonal Neoantigen Reactive T Cells at the ESMO Immuno-Oncology Annual Congress 2022

November 30, 2022

From Achilles Therapeutics PLC

Via GlobeNewswire

Achilles Therapeutics Announces Grant of US Patent on Immunotherapies Targeting Clonal Neoantigens Identified Using Proprietary Method

November 22, 2022

- US patent is for an immunotherapy targeting clonal neoantigens identified by the Achilles Clonality Engine (ACE), including vaccine, antibody, and autologous T cell therapy approaches -

From Achilles Therapeutics PLC

Via GlobeNewswire

Achilles Therapeutics Reports Third Quarter 2022 Financial Results and Recent Business Highlights

November 08, 2022

From Achilles Therapeutics PLC

Via GlobeNewswire

Achilles Therapeutics Co-founder Professor Charles Swanton to Participate in Expert Roundtable Highlighting Pivotal Nature of Neoantigens as Targets in Cancer Cell Therapy

October 06, 2022

From Achilles Therapeutics PLC

Via GlobeNewswire

5 Value Stocks To Watch In The Healthcare Sector ↗

August 08, 2022

The Meaning Behind Value Stocks A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E multiples are good base...

Via Benzinga

5 Value Stocks In The Healthcare Sector ↗

August 01, 2022

What is a Value Stock? A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E multiples are good base indicators...

Via Benzinga

Why Qudian Shares Jumped Over 40%; Here Are 73 Biggest Movers From Yesterday ↗

July 19, 2022

Gainers AMTD Digital Inc. (NYSE: HKD) climbed 71.5% to close at $27.80 on Monday after gaining 108% on Friday. The company priced its IPO at $7 per share.

Via Benzinga

Tesla, Coinbase Global And 41 Stocks Moving In Monday's Mid-Day Session ↗

July 18, 2022

Gainers Intelligent Living Application Group Inc. (NASDAQ: ILAG) shares jumped 90.2% to $4.2792 after declining 11% on Friday. The company reported closing of $20.24 million initial public offering.

Via Benzinga

Why U.S. Stocks Are Trading Higher; Goldman Sachs Tops Q2 Views ↗

July 18, 2022

U.S. stocks traded higher this morning, following earnings results from big banks.

Via Benzinga

5 Value Stocks To Watch In The Healthcare Sector ↗

June 27, 2022

What Defines a Value Stock?

Via Benzinga

Achilles Therapeutics Doses First Patient with Higher-dose cNeT in CHIRON Phase 1/2a Trial for Advanced NSCLC ↗

May 09, 2022

Achilles Therapeutics plc (NASDAQ: ACHL) announced that the first patient has been dosed with personalized clonal neoantigen-reactive T cells, or cNeT, manufactured with the Company's higher-dose...

Via Benzinga

12 Health Care Stocks Moving In Monday's After-Market Session ↗

May 02, 2022

Gainers

Via Benzinga

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

April 19, 2022

Gainers

Via Benzinga

Secarna Pharmaceuticals and Achilles Therapeutics Sign Research, Option and License Agreement to Develop Optimized T Cell Therapies

November 10, 2021

- Secarna's LNAplusTM ASOs have the potential to optimize personalized T cell therapies being developed by Achilles - Secarna's industry-leading antisense oligonucleotide (ASO) platform LNAplusTM...

From Secarna Pharmaceuticals GmbH & Co. KG

Via AccessWire

51 Biggest Movers From Yesterday ↗

October 01, 2021

Gainers Superior Drilling Products, Inc. (NYSE: SDPI) shares rose 60.6% to close at $1.75 on Thursday after jumping over 23% on Wednesday. The company, last month, reported Q2...

Via Benzinga

< Previous 1 2 3 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.